|
|
Volumn 9, Issue 2, 2008, Pages 131-135
|
|
Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine
[No Author Info available]
|
|
Author keywords
Antineoplastics, therapeutic use; Mifamurtide, therapeutic use; Osteosarcoma; Research and development
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
CPG 19835;
CPG 19835A;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FLUOROURACIL;
FOLINATE CALCIUM;
GAMMA INTERFERON;
GEMCITABINE;
GLYCOPROTEIN GP 120;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
IFOSFAMIDE;
IMMUNOMODULATING AGENT;
INTERLEUKIN 2;
MEPACT;
MIFAMURTIDE;
N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;
ORPHAN DRUG;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
ANTIVIRAL ACTIVITY;
CANCER SURVIVAL;
CHILL;
CLINICAL TRIAL;
COLORECTAL CANCER;
COMBINATION CHEMOTHERAPY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MARKETING;
DRUG SAFETY;
DYSPNEA;
FATIGUE;
FEVER;
FLU LIKE SYNDROME;
FOOD AND DRUG ADMINISTRATION;
FUNDING;
GOVERNMENT REGULATION;
HEADACHE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HYPERTENSION;
HYPOTENSION;
LICENSING;
LIVER METASTASIS;
LUNG METASTASIS;
MACROPHAGE ACTIVATION;
MELANOMA;
METASTASIS;
MONOTHERAPY;
MYALGIA;
NAUSEA;
NONHUMAN;
OSTEOSARCOMA;
OVERALL SURVIVAL;
POSTOPERATIVE CARE;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
REVIEW;
RIGOR;
SIDE EFFECT;
TACHYCARDIA;
TREATMENT OUTCOME;
TUMOR;
VIRUS REPLICATION;
ACETYLMURAMYL-ALANYL-ISOGLUTAMINE;
ADJUVANTS, IMMUNOLOGIC;
ANIMALS;
CLINICAL TRIALS AS TOPIC;
HUMANS;
PHOSPHATIDYLETHANOLAMINES;
|
|
EID: 39749103405
PISSN: 11745886
EISSN: None
Source Type: Journal
DOI: 10.2165/00126839-200809020-00007 Document Type: Review |
|
Times cited : (13)
|
|
References (20)
|